Stable Istotope Labelled Infliximab Biosimilar – Anti-TNF-alpha mAb – Research Grade

Reference: PX-TA1009-SIL-1MG
Product nameStable Istotope Labelled Infliximab Biosimilar - Anti-TNF-alpha mAb - Research Grade
SourceDrugBank DB00065
SpeciesHuman
Expression systemMammalian cells
Molecular weight144kDa
Purity>95%
BufferPBS pH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage condition4°C for short term; -20°C for long term
BrandProteoGenix
Aliases /SynonymsInfliximab
ReferencePX-TA1009-SIL
Related ProductsPX-P4641
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG1
ClonalityMonoclonal Antibody
SourceDrugBank DB00065
FormatLyophilized
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99%
Isotopic Enrichment99%
Stability1 year
FormulaC6428H9912N1694O1987S46

General information about Infliximab

Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases. This includes Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet’s disease. It is given by slow injection into a vein, typically at six- to eight-week intervals. Infliximab was originally developed in mice as a mouse antibody. Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains. They are monoclonal antibodies and have identical structures and affinities to the target. Because they are a combination of mouse and human antibody amino acid sequences, they are called a “chimeric monoclonal antibody”. This product is for research use only.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Stable Istotope Labelled Infliximab Biosimilar – Anti-TNF-alpha mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.